Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.
- DOI
- 10.1080/14787210.2022.2098113
- Published
- 2022 Oct
- Container
- Expert review of anti-infective therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14787210.2022.2098113,
title = {Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.},
author = {Elshafie AH and Elsawah HK and Hammad M and Sweed EM and Seif AS and Abdel Ghaffar MM and Goda FM and Mosalam EM and Abdallah MS},
year = {2022},
journal = {Expert review of anti-infective therapy},
doi = {10.1080/14787210.2022.2098113},
url = {https://doi.org/10.1080/14787210.2022.2098113}
}RIS
TY - JOUR TI - Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial. AU - Elshafie AH AU - Elsawah HK AU - Hammad M AU - Sweed EM AU - Seif AS AU - Abdel Ghaffar MM AU - Goda FM AU - Mosalam EM AU - Abdallah MS PY - 2022 JO - Expert review of anti-infective therapy DO - 10.1080/14787210.2022.2098113 UR - https://doi.org/10.1080/14787210.2022.2098113 ER -
APA
AH, E., HK, E., M, H., EM, S., AS, S., MM, A. G., FM, G., EM, M., & MS, A. (2022). Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.. Expert review of anti-infective therapy. https://doi.org/10.1080/14787210.2022.2098113
Source records
- pubmed · retrieved 2026-09-25T18:56:49.882Z